

apjtm.org



Original Article

Asian Pacific Journal of Tropical Medicine

doi: 10.4103/1995-7645.368018

Impact Factor: 3.041

Prevalence and risk factors associated with tuberculosis mortality in Brunei Darussalam

Liling Chaw^{1✉}, Nurul Huda Jeludin^{1,2}, Kyaw Thu²¹PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam²Disease Control Division, Department of Environmental Health Services, Ministry of Health, Bandar Seri Begawan, Brunei Darussalam

ABSTRACT

Objective: To determine the prevalence and risk factors associated with tuberculosis mortality in Brunei Darussalam and to explore its underlying causes.

Methods: A retrospective cohort study was conducted where data on socio-demographics, clinical characteristics and treatment outcomes of all tuberculosis patients registered at the National tuberculosis Coordinating Centre between 2013 and 2017 were collected. Overall tuberculosis mortality and the proportion of tuberculosis-related deaths were calculated. Logistic regression analysis was used to determine the risk factors of tuberculosis mortality when compared to those who are cured and/or completed tuberculosis treatment.

Results: Of 1 107 tuberculosis cases, 99 died, giving an overall tuberculosis mortality rate of 8.9% (95% CI 7.4%-10.8%). Significant risk factors associated with tuberculosis mortality were age ≥ 40 years (adjusted OR for 40-59 years was 3.89; 95% CI 1.13-1.69; adjusted OR for ≥ 60 years was 22.3; 95% CI 7.27-91.9, using 20-39 years as reference), female sex (adjusted OR 1.74; 95% CI 1.09-2.79), having renal disease (adjusted OR 25.7; 95% CI 2.82-191.50) and having any cancers (adjusted OR 3.61; 95% CI 1.26-10.00). The majority (75.8%) of the recorded deaths were not related to tuberculosis.

Conclusions: Tuberculosis patients who were older than 40 years, female, and having renal disease and any cancer will need close monitoring in their management program to prevent tuberculosis mortality. Clinicians should also focus on other non-tuberculosis aspects of the patient's medical history.

KEYWORDS: *Mycobacterium* infections; Tuberculosis; Mortality; Brunei

1. Introduction

Tuberculosis (TB) remains a global infectious disease of concern, with a global incidence of 7.1 million and about 1.4 million deaths in 2019, during the pre-COVID pandemic era[1]. Caused by the bacteria, *Mycobacterium tuberculosis*, active TB is highly infectious in nature but is also preventable and curable if patients adhere to their treatment regimes.

Globally, countries can be generally classified as being high and low TB burden, defined as with TB incidence of >100 and <10 cases per 100 000 population, respectively[1]. While countries with TB incidence between these two ranges were generally classified as an intermediate TB burden country. It can be generally assumed that a country's TB burden status could be positively associated with its TB-related mortality rate, previous reports does not seem to support this assumption: High TB burden country like China was found to have TB mortality of 4.56% and 14.4% in cities of Tianjin and Shanghai[2,3]. Intermediate TB burden countries (or regions)

Significance

The overall tuberculosis mortality rate was 8.9% (95% CI 7.4-10.8) in Brunei Darussalam. Older than 40 years, female sex, having renal disease and any cancer were positively associated with tuberculosis mortality. Most tuberculosis recorded deaths (75.8%) were not related to tuberculosis. Clinicians should also focus on comorbidities of the tuberculosis patients.

✉To whom correspondence may be addressed. E-mail: liling.chaw@ubd.edu.bn

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

©2023 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer-Medknow.

How to cite this article: Chaw L, Jeludin NH, Thu K. Prevalence and risk factors associated with tuberculosis mortality in Brunei Darussalam. Asian Pac J Trop Med 2023; 16(1): 9-15.

Article history: Received 28 September 2022
Accepted 10 January 2023

Revision 22 December 2022
Available online 25 January 2023

like Malaysia and Taiwan were reported to have TB mortality of 8% and 12.3%, respectively[4,5]. While low TB burden countries of Oman and USA were reported to have TB mortality of 15% and 7.3%, respectively[6,7]. This could be due to the interplay of various risk factors, other than TB incidence, that could contribute to TB mortality. Such risk factors were previously shown to be related to: (1) sociodemographic status: older age, single, low body weight, socioeconomically disadvantaged, (2) TB diagnosis and treatment (first sputum positivity, negative sputum smear TB, retreated tuberculosis, delayed visit (≥ 14 days), multidrug resistant TB, radiographic patterns showing cavitory, military and pneumonic involvement, poor TB treatment adherence) and, (3) presence of comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease, HIV positivity, immunosuppression, liver cirrhosis[6–9].

Brunei Darussalam is an intermediate TB burden country, with the TB incidence rate 54.8 per 100 000 population in 2019[10], and it has remained at similar levels since 2004[11,12]. Although deaths due to TB in the country are relatively few, and that TB was not in the country's top 10 leading causes of deaths[13], an epidemiological investigation on TB-related deaths could help determine the risk factors and cause of TB deaths in the local setting, and possibly shed some light into the stagnating TB incidence in the country. Hence, we conducted this study to: 1) determine the TB mortality, 2) identify significant risk factors associated with TB mortality and 3) investigate causes for TB mortality. The findings of this research can help in monitoring and evaluation of TB's status in Brunei Darussalam.

2. Subjects and methods

2.1. Ethical approval and patients' consent

Ethical approval was obtained from the Medical and Health Research and Ethics Committee, Ministry of Health, Brunei (ref: MHREC/UBD/2019/2). Patient informed consent was waived as data was retrospectively collected as part of the national TB surveillance, and only de-identified data was used in all analyses.

2.2. Data collection

A retrospective cohort study was conducted, where secondary data on all registered TB patients in Brunei Darussalam from January 2013 to December 2017 were collected. Three data sources were used: National TB Coordinating Centre (NTCC), National TB Reference Laboratory and Brunei Darussalam Health Information and Management System (Bru-HIMS). All TB patients in the country (identified in both government and private healthcare centers) are referred to NTCC or any of their branches in each

district for registration and continuation of their directly observed treatment. While National TB Reference Laboratory is designated solely for diagnosis and antibiotic-resistance testing for all TB-suspected sputum and tissue samples. Lastly, Bru-HIMS is an electronic patient record management system used to record data of all patients who have government clinics and hospitals since 2013[14].

2.3. Sociodemographic data

Sociodemographic data (age, sex, ethnicity and nationality) and whether they have comorbidities such as diabetes mellitus, hypertension or heart disease, chronic obstructive pulmonary disease (COPD) or asthma, renal disease, cancer or HIV/acquired immunodeficiency syndrome were for all TB patients were compiled. Clinical information on their TB diagnosis and follow-up were also collected, which includes TB status (newly diagnosed or relapsed patient), type of TB diagnosed, drug resistance to treatment, treatment outcome and causes of TB death (if the patient died).

2.4. Types of tuberculosis

Types of TB were classified into extrapulmonary TB (EPTB), smear-positive pulmonary TB (PTB), smear-negative PTB and other PTB. Diagnosis of EPTB was based on having at least one specimen with confirmed *Mycobacterium tuberculosis*, or histological evidence, or strong clinical evidence consistent with active EPTB[12]. Smear-positive pulmonary TB was diagnosed when at least one sputum smear specimen was positive for acid-fast bacilli and lung parenchyma was involved. Smear-negative PTB was diagnosed when lung parenchyma was involved but sputum smear specimen was negative and culture positive for *Mycobacterium tuberculosis*. Other PTB was diagnosed when there were radiographic abnormalities and based on clinician's decision. Drug resistance to treatment was examined for first-line drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) and streptomycin. Mono-resistant TB was defined when TB bacteria was detected to develop resistance to a single first-line TB drug. Multidrug resistant was defined when there was resistance detected to at least both isoniazid and rifampicin. Polyresistant TB was defined when there was resistance to more than one first-line TB drug, other than isoniazid and rifampicin[12].

2.5. Treatment outcomes

Treatment outcomes were categorized according to World Health Organization's reporting framework for TB: (1) cured, defined as smear- or culture- positive TB patients at the start of treatment who was smear- or culture-negative in the last month of treatment, (2)

Table 1. Sociodemographic and clinical characteristics of tuberculosis patients overall, those who had died and those who either were cured or had completed treatment in Brunei Darussalam (January 2013-December 2017) [*n* (%)].

Variable	Overall TB cases (<i>n</i> =1 107)	Died (<i>n</i> =99)	Cured or completed treatment (<i>n</i> =815)	Chi-square	P-value
Age, years, median (Q1, Q3)	46 (31, 61)	71 (56, 80)	47 (31, 61)	$\chi^2=17.635$	<0.001*
Age group, years					
0-19	76 (6.9)	1 (1.0)	73 (9.0)	69.28	<0.001*
20-39	364 (32.9)	7 (7.1)	237 (29.1)		
40-59	373 (33.7)	25 (25.2)	284 (34.8)		
>60	294 (26.5)	66 (66.7)	221 (27.1)		
Sex					
Male	679 (61.3)	53 (53.5)	491 (60.2)	1.38	0.240
Female	428 (38.7)	46 (46.4)	324 (39.8)		
Residency status					
Bruneian	834 (75.3)	95 (96.0)	733 (89.9)	3.08	0.079
Non-Bruneian	273 (24.7)	4 (4.0)	82 (10.1)		
Ethnicity					
Malay	707 (63.9)	80 (80.8)	620 (76.1)	0.86	0.355
Others	400 (36.1)	19 (19.2)	195 (23.9)		
Category of TB case					
New	1 070 (96.7)	96 (97.0)	782 (95.9)	n/a [#]	0.741
Relapse	37 (3.3)	3 (3.0)	33 (4.1)		
Type of TB					
Extrapulmonary TB	218 (19.7)	18 (18.2)	179 (22.0)	0.84	0.841
Smear-positive PTB	552 (49.9)	53 (53.5)	412 (50.6)		
Smear-negative PTB	205 (18.5)	16 (16.2)	134 (16.4)		
Other PTB	132 (11.9)	12 (12.1)	90 (11.0)		
Drug-resistance strains present					
No resistance	1 051 (94.9)	97 (98.0)	777 (95.3)	3.20	0.525
Isoniazid	21 (1.9)	0 (0.0)	14 (1.7)		
Rifampicin	0 (0.0)	0 (0.0)	0 (0.0)		
Pyrazinamide	17 (1.5)	1 (1.0)	14 (1.7)		
Ethambutol	5 (0.5)	1 (1.0)	4 (0.5)		
Streptomycin	3 (0.3)	0 (0.0)	0 (0.0)		
Polyresistance	9 (0.8)	0 (0.0)	6 (0.8)		
Multidrug resistance	1 (0.1)	0 (0.0)	0 (0.0)		
Diabetes mellitus present					
Yes	386 (34.9)	50 (50.5)	295 (36.2)	7.09	0.008*
No	721 (65.1)	49 (49.5)	520 (63.8)		
Hypertension/heart disease present					
Yes	382 (34.5)	62 (62.6)	306 (37.5)	22.06	<0.001*
No	725 (65.5)	37 (37.4)	509 (62.5)		
COPD/asthma present					
Yes	96 (8.8)	17 (17.2)	75 (9.2)	5.34	0.021*
No	1 011 (91.3)	82 (82.8)	740 (90.8)		
Renal disease present					
Yes	83 (7.5)	25 (25.3)	55 (6.7)	35.56	<0.001*
No	1 024 (92.5)	74 (74.7)	760 (93.3)		
Any cancer present					
Yes	22 (2.0)	8 (8.1)	12 (1.5)	n/a [#]	<0.001*
No	1 085 (98.0)	91 (91.9)	803 (98.5)		
HIV/AIDS present					
Yes	6 (0.5)	0 (0.0)	6 (7.4)	n/a [#]	1
No	1 101 (99.5)	99 (100.0)	809 (99.3)		

Comparison was done only between cases who have died and either cured or completed treatment, hence the numbers were less than the reported overall TB population. **P*-value showed statistical significance; χ^2 Wilcoxon test statistic; n/a[#] Test statistic is not available as Fisher's exact test was used to derive *P*-value. TB: Tuberculosis; PTB: Pulmonary tuberculosis; COPD: Chronic obstructive pulmonary disease; HIV/AIDS: Human immunodeficiency virus/acquired immunodeficiency syndrome.

completed, defined as TB patient who has completed treatment without failure but has no record of having smear- or culture-negative result in the last month of treatment, (3) treatment failure, defined as TB patient who is still smear- or culture-positive on or after fifth month of treatment, (4) died, defined as TB patients who died for any reason before or during treatment, (5) lost to follow-up, defined as TB patient who did not start treatment or whose treatment was interrupted for more than 2 consecutive months, and (6) not evaluated, defined as TB patient whose treatment outcome is unknown or those who sought treatment outside Brunei[9]. Those who were not evaluated were mainly foreign workers diagnosed with active TB at start or renewal of employment period as in accordance with *Brunei's Immigration Act*, these workers would have their employment terminated and would have to return to their home country for treatment[15].

Causes of death were acquired based on availability in Bru-HIMS, NTCC case notes or upon inference from recent case notes. Causes of TB deaths were then categorized into TB-related deaths, non-TB related deaths or unknown. For the purpose of categorizing these deaths, the treating physician's or pathologist's careful deliberation of the cause of death was utilized, and a TB-related death was only classified if TB was mentioned as a cause of death. A non-TB related death was defined as any other cause of death for which TB

was not mentioned. This included malignancy, bacterial infection, hepatic failure, renal failure, cardiovascular disease, chronic obstructive pulmonary disease with respiratory failure and others such as haemorrhage, pulmonary embolism and aortic aneurysm. Deaths were classified as unknown when there was no specific cause of death mentioned in patient's case notes.

2.6. Statistical analyses

Statistical analyses were carried out using R (ver. 4.0)[16]. Point prevalence was calculated to report on the annual trend for overall TB deaths using the formula: Prevalence=number of TB deaths/total TB cases for each year. Proportion of TB deaths according to different types of TB was also calculated (Proportion=number of deaths for different TB types/total TB deaths for each year). The 95% confidence intervals (95% CI) were also calculated and reported. Sociodemographic and clinical characteristics for the overall TB cases were analyzed. *Chi-square* or Fisher's exact tests or Mann-Whitney test (where appropriate) were performed to determine any significant differences between TB cases who had died and those who were either cured or completed treatment. The latter was chosen as the comparison group to avoid any potential bias from including cases who were classified as lost to follow-up,

Table 2. Factors associated with overall tuberculosis deaths in Brunei Darussalam (January 2013-December 2017).

Variable	Simple logistic regression				Multiple logistic regression			
	Crude OR	95% CI	Z	P value	Adjusted OR	95% CI	Z	P value
Age group, years								
0-19	0.46	0.02-2.67	-0.71	0.476	0.88	0.04-6.68	-0.11	0.911
20-39	1.00				1.00			
40-59	2.98	1.33-7.58	2.50	0.012*	3.89	1.13-1.69	2.02	0.043*
>60	10.11	4.86-24.65	5.67	<0.001*	22.30	7.27-91.90	4.91	<0.001*
Sex								
Female	1.32	0.86-2.00	-1.28	0.200	1.74	1.09-2.79	2.33	0.020*
Male	1.00				1.00			
Residency status								
Bruneian	2.66	1.08-8.84	1.87	0.062	1.72	0.64-6.10	0.96	0.337
Non-Bruneian	1.00				1.00			
Diabetes mellitus								
Yes	1.80	1.18-2.74	2.75	0.006*	5.00	0.86-26.10	1.92	0.054
No	1.00				1.00			
Hypertension/heart disease								
Yes	2.79	1.82-4.32	4.66	<0.001*	0.81	0.48-1.38	-0.79	0.431
No	1.00				1.00			
COPD/asthma								
Yes	2.05	1.12-3.56	2.45	0.015*	1.49	0.77-2.76	1.22	0.221
No	1.00				1.00			
Renal disease								
Yes	4.67	2.72-7.87	5.70	<0.001*	25.7	2.82-191.50	3.15	0.002*
No	1.00				1.00			
Any cancers								
Yes	5.88	2.25-14.60	3.77	<0.001*	3.61	1.26-10.00	2.46	0.014*
No	1.00				1.00			

*P value showed statistical significance; Interaction terms (age group and DM present; age group and renal disease present) were also included in the final model but were not shown. PTB: Pulmonary tuberculosis; COPD: Chronic obstructive pulmonary disease.

not evaluated or treatment failure. About three-quarters of all TB cases included in this study (73.6%, $n=815$) were classified as either cured or completed treatment. Variables with $P<0.1$ were further analyzed using multiple logistic regression to derive crude and adjusted odds ratios, except for age and gender which were included a priori. All regression models were checked if model assumptions were met, and interaction terms were added when necessary. Statistical significance was defined as P -value <0.05 .

3. Results

A total of 1 107 TB cases (PTB and EPTB) were reported between January 2013 and December 2017. Among them, 485 were cured, 330 completed treatment, 4 experienced treatment failure, 1 lost to follow up, 188 not evaluated, and 99 deaths occurred during the TB treatment period, giving an overall TB mortality rate of 8.9% (95% CI 7.4-10.8) during the 5-year study period.

For overall TB cases, the median age was 46 years (IQR 31-61), majority were male (679, 61.3%), Bruneian (834, 75.3%) and of Malay ethnicity (707, 63.9%; Table 2). In terms of their clinical characteristics, majority were new cases (1 070, 96.7%), smear-positive PTB (552, 49.9%), and with no drug-resistance strains (1 051, 94.9%). Initial comparative comparison analysis between TB patients who had died and those who either were cured or had completed TB treatment (Table 1) revealed significant differences in terms of age ($P<0.001$), having co-morbidities such as diabetes mellitus ($P=0.086$), hypertension or heart disease ($P<0.001$), COPD or asthma ($P=0.021$), renal disease ($P<0.001$), and any cancer ($P<0.001$). Multiple logistic regression analysis (Table 2) showed that the significant factors associated with TB deaths were advancing age (adjusted OR for 40-59 years: 3.89; 95% CI 1.13-1.69; adjusted OR for ≥ 60 years was 22.3; 95% CI 7.27-91.9, using 20-39 years as reference), being female (adjusted OR 1.74; 95% CI 1.09-2.79), having renal disease (adjusted OR 25.7; 95% CI 2.82-191.50) and having any cancers (adjusted OR 3.61; 95% CI 1.26-10.00).

Table 3. Underlying cause of deaths among tuberculosis death cases.

Causes of tuberculosis deaths	<i>n</i> (%)
Tuberculosis-related deaths	12 (12.1)
Non-tuberculosis related deaths	75 (75.8)
Malignancy	14 (14.1)
Bacterial infection	20 (20.2)
Hepatic failure	2 (2.0)
Renal failure	8 (8.1)
Cardiovascular failure	12 (12.1)
COPD with respiratory failure	5 (5.1)
Others	14 (14.1)
Unknown	12 (12.1)

COPD: Chronic obstructive pulmonary disease.

About 1/3 of the recorded deaths were not related to TB (75.8%, $n=75$; Table 3). Due to small numbers, comparison of associated

factors for TB-related deaths and non-TB related deaths was not conducted.

The annual TB mortality ranged from 7.1% to 10.9%; there was a slight increase in 2015 but then tapered off from 2016 (Figure 1). Proportion of TB deaths according to different types of TB showed higher mortality for smear-positive PTB patients, when compared to other groups (Figure 2). This is likely due to higher proportion of smear-positive PTB cases compared to the other TB types (Table 1).




Figure 1. Point prevalence of overall tuberculosis deaths among tuberculosis cases for each year (Error bars indicate the 95% confidence interval).




Figure 2. Proportion of tuberculosis deaths according to types of tuberculosis cases for each year (2013-2017). EPTB: extrapulmonary tuberculosis; PTB: pulmonary tuberculosis.

4. Discussion

During a 5-year study period, we found an overall TB mortality of 8.9% (95% CI 7.4%-10.8%) in Brunei Darussalam. Our finding is similar to that reported in another intermediate TB burden country (Malaysia, 8%)[4] and also in a low TB burden country (United States, 7.3%)[7]. But higher than that reported in a high TB burden country (Shanghai, China, 5.5%)[17], which suggests that being a high TB burden country does not necessarily equate to high TB mortality. And that other potential risk factors could

affect the risk of TB-related deaths. The significant risk factors associated with TB mortality for Brunei Darussalam were advancing age, being female, having renal disease and any cancers were positively associated with TB mortality. Our finding for advancing age was consistent with similar studies from countries with low-, intermediate, and high-TB burden[2,3,7,17–20]. Renal disease[5,7] and cancer[3] were also reported to be a risk factor with TB mortality in other studies. As older age is known to be a major risk factor in the diagnosis of chronic comorbidities, this finding may not be surprising. However, it presents a worrying scenario for Brunei specifically, as cancer was the country's main cause of death among adults[13] and also has one of the world's highest prevalence of patients undergoing kidney replacement therapy[21]. In contrast, our finding for female being positively associated with TB mortality is in conflict with other studies where male gender was reported as a risk factor[2,3,17–19]. The reason for this finding is unclear, though socio-cultural differences between genders on coping with TB disease could be one plausible explanation. Qualitative and/or questionnaire-based studies focusing on the socio-cultural aspects and well-being of TB-confirmed patients, particularly those of 40 years and older, would be helpful to confirm our findings.

We also observed that only 12.1% of all deaths were related to TB, a finding similar to Taiwan (17.3%)[5]. This suggests that in order to improve disease prognosis, it is important to also consider non-TB aspects of a patient's medical history.

This study has its limitations. First, data regarding socioeconomic status of the TB cases, any delay in treatment, treatment adherence, survival days (number of days from diagnosis to death) were not collected. These data could have provided insights and promoted changes for improvement, for example, by ensuring early diagnosis of TB in contacts to expedite treatment and prevent delays. Extending this study to include the collection of such variables would be useful to get better understanding on TB deaths in Brunei, thereby contributing towards improving TB management and the country's progress to TB elimination. Secondly, it is possible that the causes of TB deaths could be misclassified as there was only one investigator collecting the data at the time. This could have been minimized if the classification was checked and verified by another staff or a committee. Investigators tried to reduce this later on by checking case notes in Bru-HIMS. TB patients who died at home had no death records or recent case notes in Bru-HIMS so investigators were unable to determine the cause of death. Thirdly, although NTCC has been collecting TB patient data since 2000, only data from 2013 onwards could be analyzed as the latter was the year when Bru-HIMS was fully implemented. There is also a lack of death data collected at NTCC. This could have limited the study population for this study, so much so that it could have attributed to small

counts for co-morbidities and residency status. Very wide 95% CI were observed for both variables, indicating that their point estimates should be interpreted with caution. Systematic collection of patient records and/or integrating with the mortality registry would be helpful for future research.

In conclusion, we reported an overall TB mortality of 8.9% (95% CI 7.4%-10.8%) in Brunei Darussalam during a 5-year study period. Risk factors of TB mortality include advancing age, being female, and having renal disease and any cancers. Most TB deaths were not related to TB, making it important for clinicians to focus also on other non-TB aspects of the patient's history, such as the presence of comorbidities.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Data availability

The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

Funding

This study is funded by Universiti Brunei Darussalam's University Research Grant (Ref: UBD/RSCH/URC/RG(b)/2019/011).

Authors' contributions

LC and NHJ conceptualized the project idea. LC and NHJ performed the statistical analysis. KT curated the data Both NHJ and LC wrote the original draft. All authors contributed to the final version of the manuscript. KT and LC supervised the project.

References

- [1] World Health Organization. *Global tuberculosis report 2021*. [Online]. Available from: <https://www.who.int/publications/i/item/9789240037021>. [Accessed on 12 January 2021].
- [2] Xie Y, Han J, Yu W, Wu J, Li X, Chen H. Survival analysis of risk factors for mortality in a cohort of patients with tuberculosis. *Can*

- Respir J* 2020; **2020**: 1654653. doi: 10.1155/2020/1654653.
- [3] Liu Y, Zheng Y, Chen J, Shi Y, Shan LY, Wang S, et al. Tuberculosis-associated mortality and its risk factors in a district of Shanghai, China: A retrospective cohort study. *Int J Tuberc Lung Dis* 2018; **22**(6): 655-660.
- [4] Avoi R, Liaw YC. Tuberculosis death epidemiology and its associated risk factors in Sabah, Malaysia. *Int J Environ Res Public Health* 2021; **18**(18). doi:10.3390/ijerph18189740.
- [5] Lin CH, Lin CJ, Kuo YW, Wang JY, Hsu CL, Chen JM, et al. Tuberculosis mortality: Patient characteristics and causes. *BMC Infect Dis* 2014; **14**(1): 5.
- [6] Gaifer Z. Risk factors for tuberculosis mortality in a tertiary care center in Oman, 2006-2016. *Int J Mycobacteriol* 2017; **6**(4): 356.
- [7] Hannah HA, Miramontes R, Gandhi NR. Sociodemographic and clinical risk factors associated with tuberculosis mortality in the United States, 2009-2013. *Public Health Rep* 2017; **132**(3): 366-375.
- [8] Zerbini E, Greco A, Estrada S, Cisneros M, Colombo C, Beltrame S, et al. Risk factors associated with tuberculosis mortality in adults in six provinces of Argentina. *Medicina (B Aires)* 2017; **77**(4): 267-273.
- [9] World Health Organization. *Definitions and reporting framework for tuberculosis—2013 revision (Updated December 2014 and January 2020)*. [Online]. Available from: <https://www.who.int/publications/item/9789241505345>. [Accessed on 12 January 2021].
- [10] World Health Organization. Country factsheet: Public health data at a glance-Brunei Darussalam. [Online]. Available from: https://www.who.int/docs/default-source/wpro---documents/countries/brunei-darussalam/fact-sheet-brunei-darussalam.pdf?sfvrsn=b91eddf4_5. [Accessed on 1 April 2021].
- [11] Chaw L, Abdul Hamid R, Koh KS, Thu K. Contact investigation of tuberculosis in Brunei Darussalam: Evaluation and risk factor analysis. *BMJ Open Respir Res* 2022; **9**(1): e001224.
- [12] Ministry of Health Brunei Darussalam. *Guidelines for tuberculosis control in Brunei Darussalam*. [Online]. Available from: <http://www.moh.gov.bn/SitePages/Downloads.aspx>. [Accessed on 1 April 2021].
- [13] Ministry of Health Brunei Darussalam. *Health information booklet 2017 (second revision)*. 2019. [Online]. Available from: [http://moh.gov.bn/SitePages/Health Information Booklet.aspx](http://moh.gov.bn/SitePages/Health%20Information%20Booklet.aspx). [Accessed on 11 February 2020].
- [14] Ministry of Health Brunei. *Bru-HIMS*. 2020. [Online]. Available from: <https://www.moh.gov.bn/SitePages/Bru-HIMS.aspx>. [Accessed on 1 October 2020].
- [15] Laws of Brunei. *Chapter 17. Immigration*. [Online]. Available from: https://www.ilo.org/wcmsp5/groups/public/@ed_protect/@protrav/@ilo_aids/documents/legaldocument/wcms_117279.pdf. [Accessed on 12 January 2021].
- [16] R Core Team. *R: A language and environment for statistical computing*. 2021. [Online]. Available from: <http://www.r-project.org/>. [Accessed on 12 January 2021].
- [17] Shen X, DeRiemer K, Yuan Z, Shen M, Xia Z, Gui X, et al. Deaths among tuberculosis cases in Shanghai, China: Who is at risk? *BMC Infect Dis* 2009; **9**(1): 95.
- [18] Chung SY, Seon JY, Lee SH, Kim HY, Lee YW, Bae K, et al. The relationship between socio-demographic factors and tuberculosis mortality in the Republic of Korea during 2008-2017. *Front Public Heal* 2021; **9**: 1-9.
- [19] Choi H, Han K, Jung JH, Park SH, Kim SH, Kang HK, et al. Long-term mortality of tuberculosis survivors in Korea: A population-based longitudinal study. *Clin Infect Dis* 2022; doi: 10.1093/cid/ciac411.
- [20] Heunis JC, Kigozi NG, Chikobvu P, Botha S, van Rensburg HCJD. Risk factors for mortality in TB patients: A 10-year electronic record review in a South African province. *BMC Public Health* 2017; **17**(1): 38.
- [21] Lim CY, Tan J. Global dialysis perspective: Brunei Darussalam. *Kidney* 2021; **2**(6): 1027-1030.

Publisher's note

The Publisher of the *Journal* remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.